R. Hassan

Y. Pommier, J. Murai, R. Hassan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.

M. Metintaş, P. Boffetta, V. Roggli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.

I. Pastan, A. Zingone, Jingli Zhang, 2018, The journal of applied laboratory medicine.

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

D. Schrump, J. Ryś, P. Czapiewski, 2018, Human pathology.

CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?

Anish Thomas, R. Hassan, 2017, The Lancet. Oncology.

Cellular and genomic disease signature of peripheral blood mononuclear cells in patients with malignant pleural mesothelioma

R. Hassan, C. Whiting, C. Poulet, 2017 .

Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response

I. Pastan, Q. Jiang, Jingli Zhang, 2016, Clinical Cancer Research.

Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.

L. Krug, M. Maio, H. Kindler, 2013 .

Efficacy of anti‐insulin‐like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor‐I receptor sites/cell

Mitchell Ho, M. Merino, Jingli Zhang, 2012, International journal of cancer.

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

I. Pastan, P. Choyke, N. Sato, 2011, Nuclear medicine and biology.

Anti–Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts

Jingli Zhang, D. Liewehr, R. Hassan, 2007, Clinical Cancer Research.

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

I. Pastan, E. Jaffee, Anish Thomas, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UHRF1 is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

Chuong D. Hoang, M. Raffeld, W. Richards, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anaplastic lymphoma kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma.

Jun S. Wei, J. Khan, R. Kaplan, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and Pathological Features Are Still the Best Determinants ofPrognosis in Mesothelioma

R. Hassan, A.C. Miller, A. Miller, 2019 .

Clinical and pathological features are still the best determinants of prognosis in mesothelioma.

Andrew C. Miller, R. Hassan, 2012, Oncology.

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Mitchell Ho, I. Pastan, Jun Liu, 2007, Bioconjugate chemistry.

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab

P. Choyke, A. Cuthbertson, J. Roy, 2021, Cancer biotherapy & radiopharmaceuticals.

University of Birmingham Tumour-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients

Bahar, S. Steinberg, T. Greten, 2018 .

Synergistic AntitumorActivity ofTaxol and Immunotoxin SS1P inTumor-BearingMice

Mitchell Ho, I. Pastan, J. Carrasquillo, 2006 .

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

S. Steinberg, I. Pastan, D. Venzon, 2022, Cancer medicine.

Humoral Immune Response toMesothelin inMesothelioma and Ovarian Cancer Patients

Mitchell Ho, I. Pastan, Jingli Zhang, 2005 .

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

A. Mammen, J. Schlom, T. Lehky, 2018, Annals of the rheumatic diseases.

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

E. Jaffee, J. Nemunaitis, P. Illei, 2011, Clinical Cancer Research.

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

I. Pastan, Jingli Zhang, R. Hassan, 2015, Molecular Cancer Therapeutics.

Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts

S. Steinberg, K. Camphausen, T. Scott, 2006, Clinical Cancer Research.

Cancer Immunity (19 December 2007) Vol. 7, p. 20

I. Pastan, C. Iacobuzio-Donahue, E. Jaffee, 2005 .

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

R. Salgia, Melissa L. Johnson, V. Papadimitrakopoulou, 2019, Journal of Clinical Oncology.

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin

Mitchell Ho, I. Pastan, P. Azadi, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Antibody-drug conjugates for cancer therapy.

B. Teicher, Anish Thomas, R. Hassan, 2016, The Lancet. Oncology.

Immunotherapies for non-small-cell lung cancer and mesothelioma.

Anish Thomas, R. Hassan, 2012, The Lancet. Oncology.

Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma

S. Pastorino, M. Emi, M. Metintaş, 2020, Proceedings of the National Academy of Sciences.

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

S. Steinberg, I. Pastan, M. Miettinen, 2013, Science Translational Medicine.

Advances in diffuse malignant peritoneal mesothelioma

P. Sugarbaker, R. Hassan, T. Yan, 2011 .

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

I. Pastan, D. Heitjan, C. June, 2009, Proceedings of the National Academy of Sciences.

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy

K. Nagashima, Mitchell Ho, Jingli Zhang, 2011, PloS one.

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway

I. Pastan, Qi Zhou, R. Hassan, 2017, Oncotarget.

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma

S. Steinberg, I. Pastan, J. Trepel, 2019, Clinical Cancer Research.

Immunotoxin therapy of cancer.

Ira Pastan, I. Pastan, R. Kreitman, 1993, Nature reviews. Cancer.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

S. Steinberg, Y. Pommier, S. Bates, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin

Mitchell Ho, I. Pastan, J. Schlom, 2005, Clinical Cancer Research.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

K. Rosenzweig, M. Zauderer, V. Rusch, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

J. Aerts, D. Sterman, R. Hassan, 2020, Frontiers in Oncology.

Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice

Mitchell Ho, I. Pastan, J. Carrasquillo, 2006, Clinical Cancer Research.

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

I. Pastan, L. Bazhenova, H. Kindler, 2014, Clinical Cancer Research.

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

I. Pastan, C. Iacobuzio-Donahue, E. Jaffee, 2007, Cancer immunity.

Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma

I. Pastan, R. Kreitman, R. Hassan, 2000, Journal of immunotherapy.

Immunotoxin treatment of cancer.

I. Pastan, R. Kreitman, R. Hassan, 2007, Annual review of medicine.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

A. Maitra, E. Jaffee, L. Coussens, 2014, Gastroenterology.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

F. Hirsch, A. Tsao, L. Mutti, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma

S. Steinberg, Chul Kim, E. Szabo, 2017 .

Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.

G. Giaccone, S. Steinberg, I. Pastan, 2016, Lung cancer.

Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer

Alan T. Remaley, Ira Pastan, Masanori Onda, 2006, Clinical Cancer Research.

OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)

A. Mammen, S. Pittaluga, J. Schlom, 2017 .

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma

I. Pastan, D. Schrump, P. Czapiewski, 2017, Oncotarget.

Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

I. Pastan, M. Merino, Jingli Zhang, 2012, Anticancer research.

Mesothelin Expression in Human Lung Cancer

Mitchell Ho, I. Pastan, M. Willingham, 2007, Clinical Cancer Research.

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.

M. Lerner, R. Postier, D. Brackett, 2005, American journal of clinical pathology.

Clinical Presentation and Natural History of Mesothelioma: Abdominal

C. Key, C. Verschraegen, R. Hassan, 2005 .

Identification of Novel Human CTL Epitopes and TheirAgonist Epitopes ofMesothelin

Mitchell Ho, I. Pastan, J. Schlom, 2005 .

CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness

D. Schrump, P. Czapiewski, W. Biernat, 2020, The Journal of pathology.

New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

C. Verschraegen, N. Heintz, B. Mossman, 2013, The American journal of pathology.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

J. Nemunaitis, C. Verschraegen, A. von Heydebreck, 2019, JAMA oncology.

Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression.

Y. Pommier, M. Raffeld, R. Chari, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Binding Domain on Mesothelin for CA125/MUC16*

Mitchell Ho, Byungkook Lee, Jingli Zhang, 2009, Journal of Biological Chemistry.

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

S. Steinberg, Jun S. Wei, A. Ghafoor, 2021, JTO clinical and research reports.

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

S. Steinberg, I. Pastan, A. Italiano, 2020, Cancer.

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models

S. Steinberg, I. Pastan, A. Ghafoor, 2020, Science Translational Medicine.

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

J. Nemunaitis, J. Bendell, B. Childs, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TÜBERKÜLOZ ve TORAKS TUBERCULOSIS and THORAX

A. Simonds, A. Anzueto, G. Hillerdal, 2011 .

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Ira Pastan, I. Pastan, R. Kelly, 2012, Molecular Cancer Therapeutics.

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity

I. Pastan, Jingli Zhang, M. Onda, 2016, Oncotarget.

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab

S. Steinberg, F. Guadagni, J. Schlom, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients

N. Nicolaides, L. Grasso, Wenquan Wang, 2018, Cancer biology & therapy.

Anaplastic lymphoma kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma.

Jun S. Wei, R. Kaplan, D. Schrump, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma

E. Ruppin, Jun S. Wei, J. Lee, 2023, Cell reports. Medicine.

Transcriptomics based prediction of survival and response to therapy in malignant mesothelioma

E. Ruppin, Jun S. Wei, J. Lee, 2022, bioRxiv.

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice

I. Pastan, Jingli Zhang, R. Hassan, 2014, PloS one.

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)

C. Cleeland, T. Mendoza, C. Elbi, 2019, Journal of Patient-Reported Outcomes.

Immunotherapeutic Approaches to Mesothelioma

Anish Thomas, R. Hassan, M. Badrinath, 2017 .

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

D. Baker, I. Pastan, Byungkook Lee, 2014, Proceedings of the National Academy of Sciences.

Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.

I. Pastan, Jingli Zhang, O. Chertov, 2011, Cancer research.

In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice

Mitchell Ho, M. Anver, Jingli Zhang, 2011, Journal of Cancer.

Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma

Mitchell Ho, I. Pastan, S. Nagata, 2006, Clinical Cancer Research.

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

I. Pastan, Byungkook Lee, R. Kreitman, 2012, Proceedings of the National Academy of Sciences.

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

S. Steinberg, I. Pastan, Jingli Zhang, 2014, Cancer.

A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.

Mitchell Ho, I. Pastan, M. Onda, 2010, Cancer research.

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

I. Pastan, R. Hassan, Laiman Xiang, 2007, Proceedings of the National Academy of Sciences.

Anti-Mesothelin Immunotoxin and Immune Suppression Major Cancer Regressions in Mesothelioma After Treatment with an

S. Steinberg, I. Pastan, M. Miettinen, 2013 .

Targeting mesothelin in ovarian cancer

A. Ghafoor, Anish Thomas, R. Hassan, 2018, Oncotarget.

Fluorescence In Situ Hybridization

G. Giaccone, S. Steinberg, I. Pastan, 2020, Definitions.

Acute Myeloid Leukemia Following Treatment with Cladribine for Hairy Cell Leukemia: A Case Report and Review of the Literature

W. Kern, R. Hassan, H. Ozer, 2004, Leukemia & lymphoma.

CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma

D. Schrump, Satoru Takahashi, P. Czapiewski, 2023, The journal of pathology. Clinical research.

Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.

J. Nemunaitis, C. Verschraegen, A. Dowlati, 2018 .

Farletuzumab in lung cancer.

Anish Thomas, R. Hassan, J. Maltzman, 2013, Lung cancer.

Uluslararasi Danişma Kurulu/International Advisory Board

A. Simonds, P. Factor, A. Anzueto, 2014 .

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

H. Kindler, S. Antonia, Anish Thomas, 2015, Journal of Immunotherapy for Cancer.

Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).

K. McDougall, H. Kindler, S. Antonia, 2014 .

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

Mitchell Ho, I. Pastan, Q. Jiang, 2022, Molecular cancer therapeutics.

Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.

D. Schrump, M. Miettinen, Andrew C. Miller, 2014, Annals of the American Thoracic Society.

280 Updated results of the phase I study of SS1(dsFv)PE38 for targeted therapy of mesothelin expressing cancers

I. Pastan, H. Kindler, R. Hassan, 2004 .

Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.

M. King, S. Steinberg, Jun S. Wei, 2018 .

Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations.

Chuong D. Hoang, V. Rusch, S. Pastorino, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer

I. Pastan, E. Jaffee, D. Laheru, 2008 .

Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2013 .

Vascular Endothelial Growth Factor in Predicting Outcome in Breast Cancer

I. Pastan, U. Langsenlehner, W. Renner, 2004, Clinical Cancer Research.

Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health

A. Metwalli, Anish Thomas, A. Semerjian, 2017, Clinical genitourinary cancer.

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

A. Ghafoor, J. Tanyi, D. Oh, 2023, Nature Medicine.

3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial

J. Nemunaitis, A. Heydebreck, J. Gulley, 2015 .